Inhibikase Swaps Auditors, Dropping CohnReznick for Deloitte
IKT sits 93% above its 52-week low of $1.33.
Summary
Inhibikase Therapeutics dismissed CohnReznick as its independent auditor and appointed Deloitte & Touche, effective August 21, 2026. The filing notes a previously remediated material weakness from fiscal year 2024 but no disagreements or adverse opinions.
Key Events · Corporate Governance and Compliance · IKT
-
Auditor Dismissal
The Audit Committee dismissed CohnReznick LLP as the independent registered public accounting firm, effective August 21, 2026.
-
New Auditor Appointed
Deloitte & Touche LLP was appointed as the new independent registered public accounting firm for the fiscal year ending December 31, 2026, effective immediately following CohnReznick's dismissal.
-
Prior Material Weakness Disclosed
CohnReznick had advised the company of a material weakness in internal control over financial reporting during fiscal year 2024, which was subsequently remediated by prior management.
-
No Disagreements or Adverse Opinions
CohnReznick's audit reports for fiscal years 2025 and 2024 contained no adverse opinion or disclaimer of opinion, and there were no disagreements on accounting principles or practices.
Analysis · IKT · Life Sciences
Effective August 21, 2026, Inhibikase Therapeutics dismissed its auditor CohnReznick and immediately brought in Deloitte & Touche. The filing notes that CohnReznick's audit reports for fiscal years 2025 and 2024 contained no adverse opinion or disclaimer of opinion, and there were no disagreements on accounting principles or practices. However, it also reveals that CohnReznick had previously advised the company of a material weakness in internal control over financial reporting during fiscal year 2024, which was subsequently remediated by prior management. Auditor changes are a governance red flag that investors scrutinize closely, especially when a material weakness was previously identified. The appointment of a Big Four firm like Deloitte may be viewed as a positive step toward stronger financial controls, but the abrupt dismissal of the prior auditor without a stated reason raises questions about the timing and motivation behind the change.
How filings like this one have moved
In the 30 days to Sep 14, 2026, 35.8% of the 1045 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.43%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, IKT was trading at $2.57 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $348.8M. The 52-week trading range was $1.33 to $2.54. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.